Description
This active moleculr is a Os(II) anticancer drug candidate. It can generate reactive oxygen species and disrupt the redox balance in cancer cells. Using FY26 and nontoxic doses of L-BSO together allows the potentiation of its anticancer activity and inpartantly, it improves the selectivity for cancer cells versus normal fibroblasts. FY26 can shut down a cancer cell by exploiting weaknesses inherent in their energy generation